Long‐term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP‐ritux
Résumé
Rituximab is a second-line option in adults with immune thrombocytopenia (ITP), but the estimated 5-year response rate, only based on pooled retrospective data, is about 20%, and no studies have focused on long-term safety. We conducted a prospective multicenter registry of 248 adults with ITP treated with rituximab with 5 years of
Fichier principal
American J Hematol - 2019 - Deshayes - Long‐term safety and efficacy of rituximab in 248 adults with immune.pdf (2.22 Mo)
Télécharger le fichier
| Origine | Publication financée par une institution |
|---|